InterventionsHumans

Effect of Combination Therapy With GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes and ASCVD: A Systematic Review and Meta-analysis

AHA Scientific Sessions 2025 Abstract

The paper

Midori Torpoco Rivers, Steven E. Hopkins, Jonathan S. Zawadzki,

Inês Martins Esteves, Ryan M. Rivosecchi,

University of Pittsburgh Medical Center

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4357466

doi.org/10.1161/circ.152.suppl_3.4357466

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
The American Journal of Cardiology · 8 Oct 2026